Choose Your Country or Region

Histone Methyltransferase

Isoform-selective Products

Menin-MLL interaction WDR5-MLL interaction

Signaling Pathway

Histone Methyltransferase Products

All (82)
Histone Methyltransferase Inhibitors (62)
Histone Methyltransferase Antagonists (3)
New Histone Methyltransferase Products

Catalog No.	Product Name	Information	Product Use Citations
S7061	GSK126	GSK126 (GSK2816126A, GSK2816126) is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, >1000-fold selective for EZH2 over 20 other human methyltransferases.	Oncogene, 2025, 44(6):391-405 Sci Adv, 2025, 11(11):eadr4443 bioRxiv, 2025, 2025.02.07.637189
S7128	Tazemetostat (EPZ-6438)	Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with K_i and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.	Nat Cancer, 2025, 10.1038/s43018-025-00960-z Nat Commun, 2025, 16(1):1325 Nucleic Acids Res, 2025, 53(4)gkaf107
S7120	DZNeP (3-deazaneplanocin A) HCl	DZNeP (3-deazaneplanocin A) HCl, an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with K_i of 50 pM in a cell-free assay.	Nan Fang Yi Ke Da Xue Xue Bao, 2025, 45(2):322-330 Elife, 2024, 12RP86978 EMBO Rep, 2024, 10.1038/s44319-024-00343-y
S7164	GSK343	GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM in a cell-free assay, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. GSK343 induces autophagy.	Cell, 2025, S0092-8674(25)00396-4 Research (Wash D C), 2025, 8:0602 Commun Biol, 2024, 7(1):1535
S7062	Pinometostat (EPZ5676)	Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with K_i of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.	Cell Biosci, 2024, 14(1):93 Int J Mol Sci, 2024, 25(11)6020 Heliyon, 2024, 10(13):e33736
S8006	BIX-01294 trihydrochloride	BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay, reduces H3K9me2 of bulk histones, also weakly inhibits GLP (primarily H3K9me3), no significant activity observed at other histone methyltransferases. BIX01294 induces autophagy. BIX01294 also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3.	Clin Transl Med, 2025, 15(1):e70164 Mol Metab, 2025, 94:102113 Acta Pharm Sin B, 2024, 14(3):1187-1203
S7353	EPZ004777	EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM in a cell-free assay and demonstrates >1,200-fold selectivity for DOT1L over all other tested PMTs. EPZ004777 induces apoptosis.	Cell Rep, 2023, 42(8):112885 Cell Rep, 2023, 42(6):112566 Int J Mol Sci, 2023, 24(11)9365
S7748	EPZ015666 (GSK3235025)	EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with K_i of 5 nM, >20,000-fold selectivity over other PMTs.	Cell Rep, 2024, 43(11):114930 Oncogene, 2024, 10.1038/s41388-024-03049-6 Elife, 2024, 12RP89754
S7165	UNC1999	UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.	Cell Stem Cell, 2025, S1934-5909(25)00041-4 Nat Commun, 2024, 15(1):7366 bioRxiv, 2024, 2024.11.21.624171
S8496	EED226	EED226 is a potent, selective, and orally bioavailable a novel allosteric Polycomb repressive complex 2 (PRC2) inhibitor with an IC50 of 23.4 nM when the H3K27me0 peptide was used as substrate and an IC50 of 53.5 nM when the mononucleosome was used as the substrate. It directly binds to the H3K27me3 binding pocket of EED.	Cell Rep, 2025, 44(3):115362 Elife, 2023, 12e85365 Elife, 2023, 12e85365
S7004	EPZ005687	EPZ005687 is a potent and selective inhibitor of EZH2 with K_i of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.	Commun Biol, 2024, 7(1):1535 J Exp Clin Cancer Res, 2023, 42(1):320 BMC Med, 2022, 20(1):189
S8068	Chaetocin	Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR).	Research (Wash D C), 2025, 8:0602 Cell Rep, 2025, 44(6):115742 Int J Mol Sci, 2024, 25(17)9215
S7079	SGC 0946	SGC 0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM in a cell-free assay, is inactive against a panel of 12 PMTs and DNMT1.	Nat Commun, 2024, 15(1):10787 Life Sci Alliance, 2024, 7(4)e202302424 Sci Adv, 2024, 10(38):eadn7724
S8664	Pemrametostat (GSK3326595)	Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models.	J Med Chem, 2025, 68(4):4217-4236 J Med Chem, 2025, 68(5):5097-5119 NPJ Precis Oncol, 2024, 8(1):52
S7265	MM-102	MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic inhibitor of the WDR5/MLL1 protein-protein interaction, which bind to WDR5 with Ki < 1 nM and IC50 =2.4nM.This product may precipitate when dissolved in saline solution or PBS solution. It is recommended to prepare the stock solution in DMSO solution.	Cell Rep Med, 2025, 6(2):101928 Clin Transl Med, 2025, 15(2):e70217 FASEB J, 2025, 39(8):e70543
S8071	UNC0638	UNC0638 is a potent, selective and cell-penetrant chemical probe for G9a and GLP histone methyltransferase with IC50 of <15 nM and 19 nM, respectively, shows selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 has anti-viral activities.	Cell Rep, 2024, 43(2):113779 Exp Hematol, 2024, 142:104691 bioRxiv, 2024, 2024.12.18.629181
S7805	EPZ011989	EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with K_i of <3 nM.	Cancers (Basel), 2024, 16(3):569. Cancers (Basel), 2024, 16(3)569 Sci Adv, 2024, 10(13):eadk4423
S7230	UNC0642	UNC0642 is a potent, selective inhibitor of histone methyltransferases G9a/GLP with IC50s less than 2.5 nM for G9a and GLP and shows more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels.	Cell Death Discov, 2025, 11(1):31 PLoS Biol, 2024, 22(3):e3002240 Cell Rep, 2024, 43(1):113575
S7833	OICR-9429	OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.	FASEB J, 2025, 39(8):e70543 Mol Cell, 2024, 84(8):1475-1495.e18 PLoS Biol, 2024, 22(3):e3002240
S7570	UNC0379	UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.3 μM, high selectivity over 15 other methyltransferases.	Mol Cancer, 2025, 24(1):102 Cell Death Dis, 2025, 16(1):226 Res Sq, 2024, rs.3.rs-4603170
S8111	GSK591	GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 4 nM.	J Immunother Cancer, 2025, 13(4)e011299 J Clin Invest, 2024, e175023 Cancer Lett, 2024, 604:217263
S8353	Lirametostat (CPI-1205)	Lirametostat (CPI-1205) is an orally available selective inhibitor of the histone lysine methyltransferase EZH2 with IC50 values of 2 nM and 52 nM for EZH2 and EZH1 respectively. It has potential antineoplastic activity.	Sci Adv, 2024, 10(13):eadk4423 JCI Insight, 2022, e155899 Cancer Discov, 2021, candisc.0913.2020
S7618	MI-2 (Menin-MLL Inhibitor)	MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.	ProQuest, 2023, 30484965 Cell Stem Cell, 2022, S1934-5909(22)00417-9 Life Sci Alliance, 2022, 5(4)e202101187
S7616	CPI-169	CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.	J Exp Clin Cancer Res, 2023, 42(1):96 J Exp Clin Cancer Res, 2023, 42(1):96 Nat Commun, 2022, 13(1):6226
S7817	MI-503	MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations.	Nat Genet, 2025, 57(1):165-179 Sci Rep, 2025, 15(1):7059 Sci Adv, 2024, 10(11):eadk0785
S8112	MS023	MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.	Biol Direct, 2025, 20(1):60 Hepatol Commun, 2025, 9(4)e0647 J Immunother Cancer, 2024, 12(9)e009603
S7983	A-196	A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50 values of 0.025 and 0.144 μM, respectively; more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.	iScience, 2023, 26(3):106158 Cancer Res, 2022, 82(8):1534-1547 Sci Total Environ, 2022, 838(Pt 1):155713
S7804	GSK503	GSK503 is a potent and specific EZH2 methyltransferase inhibitor.	JCI Insight, 2025, e177545 Int J Mol Sci, 2023, 24(10)8603 Cancer Res, 2022, CAN-22-0736
S7884	AMI-1	AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.	Cell Death Dis, 2023, 14(4):233 Oncogenesis, 2022, 11(1):45 Oncogene, 2021, 40(7):1375-1389
S7294	PFI-2 HCl	PFI-2 is a potent, selective, and cell-active lysine methyltransferase SETD7 inhibitor with K_{i (app)} and IC50 of 0.33 nM and 2 nM, 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.	Biochem Biophys Res Commun, 2024, 708:149808 Life Sci Alliance, 2023, 6(5)e202201619 Pharmacol Res, 2022, 177:106122
S7832	SGC707	SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and K_d of 31 nM and 53 nM, respectively.	Cell Death Dis, 2022, 13(11):943 J Med Chem, 2020, 31 Transpl Int, 2020, 33(2):229-243
S7572	A-366	A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor with IC50 of 3.3nM and 38nM, exhibiting >1000-fold selectivity for G9a/GLP over 21 other methyltransferases.	Cell Rep, 2024, 43(1):113575 Cell Mol Life Sci, 2024, 81(1):128 Cancers (Basel), 2023, 15(8)2199
S4589	Amodiaquine dihydrochloride dihydrate	Amodiaquine is a potent, non-competitive inhibitor of histamine N-methyl transferase with estimated Ki of 18.6 nM. It is also used as an antimalarial and anti-inflammatory agent.	Cell Death Differ, 2023, 10.1038/s41418-023-01167-4 Nat Biomed Eng, 2021, 10.1038/s41551-021-00718-9 J Med Chem, 2020, 31
S7619	MI-3 (Menin-MLL Inhibitor)	MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.	Cell Rep, 2025, 44(1):115219 Nat Commun, 2023, 14(1):3062 University of Calgary, 2023,
S7591	BRD4770	BRD4770 is a histone methyltransferase G9a inhibitor with IC50 of 6.3 μM, and induces cell senescence.	Adv Healthc Mater, 2024, e2401192. Hum Cell, 2023, 10.1007/s13577-023-00924-4 Cell Insight, 2023, 2(4):100112
S7575	LLY-507	LLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2.	Acta Pharm Sin B, 2024, 14(2):712-728 Pharmacol Res, 2022, 177:106122 Oncol Lett, 2020, 20(5):153
S8624	Onametostat (JNJ-64619178)	Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.	Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9 Sci Rep, 2024, 14(1):4303 SLAS Discov, 2024, 29(4):100161
S2184	WDR5-0103	WDR5-0103 (WD-Repeat Protein 5-0103) is a small-molecule antagonist of WDR5 (WD40 repeat protein 5) with Kd of 450 nM.	J Clin Invest, 2023, 133(13)e169993 Cancer Res, 2023, 83(16):2750-2762 Cell Rep, 2023, 42(9):113145
S7611	EI1	EI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.	NPJ Precis Oncol, 2025, 9(1):7 Cancer Res, 2018, 78(20):5731-5740 Elife, 2018, 7e35368
S4021	Tolcapone	Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with K_i of 30 nM.	FASEB J, 2022, 36(7):e22399 Viruses, 2021, 13(8)1533 Front Bioinform, 2021, 1:710591
S8359	UNC3866	UNC3866 is a potent antagonist of the methyllysine (Kme) reading function of the Polycomb CBX and CDY families of chromodomains. UNC3866 binds the chromodomains of CBX4 and CBX7 most potently, with a K(d) of ∼100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodomains.	Leukemia, 2021, 10.1038/s41375-021-01121-8 Leukemia, 2021, 10.1038/s41375-021-01121-8 Int J Mol Sci, 2021, 22(2)E619
S7820	EPZ020411 2HCl	EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM.	Theranostics, 2024, 14(10):4090-4106 Nat Commun, 2023, 14(1):1430 Inflamm Res, 2022, 71(3):309-320
S7816	MI-463	MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.	J Clin Invest, 2023, 133(13)e169993 iScience, 2023, 26(10):107726 iScience, 2023, 26(10):107726
S8209	HLCL-61 HCL	HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia.	Front Immunol, 2019, 10:174 Nat Commun, 2018, 9(1):1572 Cancer Res, 2018, 78(20):5731-5740
S8983	MAK683	MAK683 (EED inhibitor-1, example 2) is an inhibitor of embryonic ectoderm development (EED). MAK683 exhibits IC50 of 59 nM, 89 nM and 26 nM in EED Alphascreen binding, LC-MS and ELISA assay, respectively.	Nature, 2024, 10.1038/s41586-024-08031-6 Mol Cell, 2024, 84(20):3885-3898.e8 J Biol Chem, 2024, 300(10):107765
S7815	MI-136	MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes.	Breast Cancer Res, 2022, 24(1):52 Cancer Cell Int, 2022, 22(1):336 J Med Chem, 2020, 31
S3147	Entacapone	Entacapone (OR-611) inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM. Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.	Elife, 2022, 11e72668 bioRxiv, 2021, 10.1101/2021.03.22.436393
S8147	MS049	MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively.	Theranostics, 2024, 14(10):4090-4106 Front Cell Dev Biol, 2021, 9:741736 Research Square, 2021, 10.21203/rs.3.rs-620216/v1
S7868	SAH (S-Adenosyl-L-homocysteine)	SAH (S-Adenosyl-L-homocysteine) is an inhibitor for (Methyltransferase Like 3-14) METTL3-METTL14 heterodimer complex (METTL3-14) with IC50 of 0.9 μM.	Clin Epigenetics, 2024, 16(1):18 Int J Mol Sci, 2024, 25(8)4538 Heliyon, 2023, 9(6):e16905
S8934	VTP50469	VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity.	Cell Rep Med, 2024, S2666-3791(24)00179-4 Sci Adv, 2024, 10(11):eadk0785 Cell Rep, 2023, 42(6):112547
S8494	PF-06726304	PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.	NPJ Precis Oncol, 2025, 9(1):7 Nat Commun, 2023, 10.1038/s41467-023-42930-y Elife, 2021, 10e65654
S7656	CPI-360	CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.	Mol Ther Oncolytics, 2022, 27:14-25 Cancer Res, 2018, 78(20):5731-5740
S8607	JQ-EZ-05 (JQEZ5)	JQ-EZ-05 (JQEZ5) is a specific and reversible EZH1/2 inhibitor.	Nat Chem Biol, 2019, 15(4):391-400
S8340	SGC2085	SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.	Clin Exp Med, 2025, 25(1):102 Redox Biol, 2024, 78:103414 Cell Rep, 2022, 39(12):110994
S7610^New	UNC0631	UNC 0631 is a potent inhibitor of histone methyltransferase G9a with an IC50 of 4 nM. It potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 25 nM.	Cancer Res, 2018, 78(20):5731-5740
F0057^New	Histone H3 Rabbit mAb		Nanotoxicology, 2021, 15(6):779-797
F0165^New	Histone H3 (tri methyl Lys 27) Rabbit mAb	Histone H3 (tri methyl K27),trimethyl-Histone H3 (Lys27),Tri-Methyl-Histone H3 (Lys27),Trimethyl-Histone H3 (Lys27) - ChIP Validated
F1000	METTL3 Rabbit mAb
F1391	METTL14 Rabbit mAb
F2053	Histone H3.3 Rabbit mAb	Histone H3.3, H3-3A, H3.3A, H3F3, H3F3A, H3-3B, H3.3B, H3F3B, Histone H3.1, Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, H3C1, H3FA, HIST1H3A, H3C2, H3FL, HIST1H3B, H3C3, H3FC, HIST1H3C, H3C4, H3FB, HIST1H3D, H3C6, H3FD, HIST1H3E
F0784^New	Histone H2B Rabbit mAb	Histone H2B
F2863^New	Tri-Methyl-Histone H3 (Lys4) (J19C19) Rabbit mAb	ChIPAb+ Trimethyl-Histone H3 (Lys4) - ChIP Validated,Histone H3 (tri methyl K4),Trimethyl Histone H3 (Lys4),Trimethyl-Histone H3 (Lys4),Tri-Methyl-Histone H3 (Lys4)
F0669^New	Acetyl-Histone H3 (Lys18) Rabbit mAb	Acetyl-Histone H3 (Lys18),Histone H3 (acetyl K18)
F0329^New	Di-Methyl-Histone H3 (Lys27) Rabbit mAb	dimethyl-Histone H3 (Lys27),Di-Methyl-Histone H3 (Lys27),Histone H3 (di methyl K27)	Front Cell Dev Biol, 2025, 13:1566567
F1267^New	Tri-Methyl-Histone H4 (Lys20) Rabbit mAb	Histone H4 (tri methyl K20),trimethyl-Histone H4 (Lys20),Tri-Methyl-Histone H4 (Lys20)
F0639^New	Mono-Methyl-Histone H3 (Lys 4) Rabbit mAb	Histone H3 (mono methyl K4),monomethyl-Histone H3 (Lys4),Mono-Methyl-Histone H3 (Lys4)
F2529^New	Histone H3 (tri methyl Lys 27) mAb	Histone H3 (tri methyl K27),trimethyl-Histone H3 (Lys27),Tri-Methyl-Histone H3 (Lys27),Trimethyl-Histone H3 (Lys27) - ChIP Validated
F3394^New	Histone H3 (tri methyl Lys 9) Rabbit mAb	Histone H3 (tri methyl K9),Histone H3 [Trimethyl Lys9],trimethyl-Histone H3 (Lys9),Tri-Methyl-Histone H3 (Lys9)
F0307^New	SUZ12 Rabbit mAb
F3402^New	Histone H3 (mono methyl Lys 4) Rabbit mAb	Histone H3 (mono methyl K4),monomethyl-Histone H3 (Lys4),Mono-Methyl-Histone H3 (Lys4)
F0365^New	Tri-Methyl-Histone H3 (Lys4) Rabbit mAb	ChIPAb+ Trimethyl-Histone H3 (Lys4) - ChIP Validated,Histone H3 (tri methyl K4),Trimethyl Histone H3 (Lys4),Trimethyl-Histone H3 (Lys4),Tri-Methyl-Histone H3 (Lys4)
S8070^New	UNC0224	UNC0224 is a potent and selective inhibitor G9a with an IC50 of 15 nM and a Kd of 23 nM. It can be a useful tool for investigating the biology of G9a and its roles in chromatin remodeling.
S7020	UNC0646	UNC0646 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM , respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.
E1163	MS177	MS177 is an EZH2-targeting PRTOAC degrader and a potent inhibitor of enzymatic EZH2, that effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukemia cell growth inhibition, apoptosis, and cell cycle progression arrest.
E1728	STC-15	STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.
S6696^New	EZM 2302 (GSK3359088)	EZM2302 is an inhibitor of CARM1 enzymatic activity in biochemical assays(IC50 = 6 nM) with broad selectivity against other histone methyltransferases.
S5445	AMI-1 (free acid)	AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
S8918	MS1943	MS1943 is an orally bioavailable EZH2 selective degrader that effectively reduces EZH2 levels in cells with IC50 of 120 nM for inhibiting EZH2 methyltransferase activity.	Nat Commun, 2024, 15(1):9755
E2911	UZH2	UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM in TR-FRET assay.
S8702	EBI-2511	EBI-2511 is a highly potent and orally active EZH2 inhibitor with an IC50 of 4 nM for EZH2(A667G).
S9659	UNC6852	UNC6852 is a selective degrader that targets polycomb repressive complex 2 (PRC2) with IC50 of 247 nM for EED. UNC6852 is based on PROTAC and contains an EED226-derived ligand and a ligand for VHL.
E1967^New	ORIC-944	ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. It exhibits anti-tumor activity in vivo prostate cancer models.
S7061	GSK126	GSK126 (GSK2816126A, GSK2816126) is a potent, highly selective EZH2 methyltransferase inhibitor with IC50 of 9.9 nM, >1000-fold selective for EZH2 over 20 other human methyltransferases.	Oncogene, 2025, 44(6):391-405 Sci Adv, 2025, 11(11):eadr4443 bioRxiv, 2025, 2025.02.07.637189
S7128	Tazemetostat (EPZ-6438)	Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with K_i and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.	Nat Cancer, 2025, 10.1038/s43018-025-00960-z Nat Commun, 2025, 16(1):1325 Nucleic Acids Res, 2025, 53(4)gkaf107
S7120	DZNeP (3-deazaneplanocin A) HCl	DZNeP (3-deazaneplanocin A) HCl, an analog of adenosine, is a competitive inhibitor of S-adenosylhomocysteine hydrolase with K_i of 50 pM in a cell-free assay.	Nan Fang Yi Ke Da Xue Xue Bao, 2025, 45(2):322-330 Elife, 2024, 12RP86978 EMBO Rep, 2024, 10.1038/s44319-024-00343-y
S7164	GSK343	GSK343 is a potent and selective EZH2 inhibitor with IC50 of 4 nM in a cell-free assay, showing 60 fold selectivity against EZH1, and >1000 fold selectivity against other histone methyltransferases. GSK343 induces autophagy.	Cell, 2025, S0092-8674(25)00396-4 Research (Wash D C), 2025, 8:0602 Commun Biol, 2024, 7(1):1535
S7062	Pinometostat (EPZ5676)	Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with K_i of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. Phase 1.	Cell Biosci, 2024, 14(1):93 Int J Mol Sci, 2024, 25(11)6020 Heliyon, 2024, 10(13):e33736
S8006	BIX-01294 trihydrochloride	BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM in a cell-free assay, reduces H3K9me2 of bulk histones, also weakly inhibits GLP (primarily H3K9me3), no significant activity observed at other histone methyltransferases. BIX01294 induces autophagy. BIX01294 also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3.	Clin Transl Med, 2025, 15(1):e70164 Mol Metab, 2025, 94:102113 Acta Pharm Sin B, 2024, 14(3):1187-1203
S7353	EPZ004777	EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM in a cell-free assay and demonstrates >1,200-fold selectivity for DOT1L over all other tested PMTs. EPZ004777 induces apoptosis.	Cell Rep, 2023, 42(8):112885 Cell Rep, 2023, 42(6):112566 Int J Mol Sci, 2023, 24(11)9365
S7748	EPZ015666 (GSK3235025)	EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with K_i of 5 nM, >20,000-fold selectivity over other PMTs.	Cell Rep, 2024, 43(11):114930 Oncogene, 2024, 10.1038/s41388-024-03049-6 Elife, 2024, 12RP89754
S7165	UNC1999	UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.	Cell Stem Cell, 2025, S1934-5909(25)00041-4 Nat Commun, 2024, 15(1):7366 bioRxiv, 2024, 2024.11.21.624171
S7004	EPZ005687	EPZ005687 is a potent and selective inhibitor of EZH2 with K_i of 24 nM in a cell-free assay, 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.	Commun Biol, 2024, 7(1):1535 J Exp Clin Cancer Res, 2023, 42(1):320 BMC Med, 2022, 20(1):189
S8068	Chaetocin	Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively. Chaetocin is an anticancer agent and inhibitor of thioredoxin reductase (TrxR).	Research (Wash D C), 2025, 8:0602 Cell Rep, 2025, 44(6):115742 Int J Mol Sci, 2024, 25(17)9215
S7079	SGC 0946	SGC 0946 is a highly potent and selective DOT1L methyltransferase inhibitor with IC50 of 0.3 nM in a cell-free assay, is inactive against a panel of 12 PMTs and DNMT1.	Nat Commun, 2024, 15(1):10787 Life Sci Alliance, 2024, 7(4)e202302424 Sci Adv, 2024, 10(38):eadn7724
S8664	Pemrametostat (GSK3326595)	Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models.	J Med Chem, 2025, 68(4):4217-4236 J Med Chem, 2025, 68(5):5097-5119 NPJ Precis Oncol, 2024, 8(1):52
S7265	MM-102	MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic inhibitor of the WDR5/MLL1 protein-protein interaction, which bind to WDR5 with Ki < 1 nM and IC50 =2.4nM.This product may precipitate when dissolved in saline solution or PBS solution. It is recommended to prepare the stock solution in DMSO solution.	Cell Rep Med, 2025, 6(2):101928 Clin Transl Med, 2025, 15(2):e70217 FASEB J, 2025, 39(8):e70543
S8071	UNC0638	UNC0638 is a potent, selective and cell-penetrant chemical probe for G9a and GLP histone methyltransferase with IC50 of <15 nM and 19 nM, respectively, shows selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 has anti-viral activities.	Cell Rep, 2024, 43(2):113779 Exp Hematol, 2024, 142:104691 bioRxiv, 2024, 2024.12.18.629181
S7805	EPZ011989	EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with K_i of <3 nM.	Cancers (Basel), 2024, 16(3):569. Cancers (Basel), 2024, 16(3)569 Sci Adv, 2024, 10(13):eadk4423
S7230	UNC0642	UNC0642 is a potent, selective inhibitor of histone methyltransferases G9a/GLP with IC50s less than 2.5 nM for G9a and GLP and shows more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels.	Cell Death Discov, 2025, 11(1):31 PLoS Biol, 2024, 22(3):e3002240 Cell Rep, 2024, 43(1):113575
S7570	UNC0379	UNC0379 is a selective, substrate competitive inhibitor of N-lysine methyltransferase SETD8 with IC50 of 7.3 μM, high selectivity over 15 other methyltransferases.	Mol Cancer, 2025, 24(1):102 Cell Death Dis, 2025, 16(1):226 Res Sq, 2024, rs.3.rs-4603170
S8111	GSK591	GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 4 nM.	J Immunother Cancer, 2025, 13(4)e011299 J Clin Invest, 2024, e175023 Cancer Lett, 2024, 604:217263
S8353	Lirametostat (CPI-1205)	Lirametostat (CPI-1205) is an orally available selective inhibitor of the histone lysine methyltransferase EZH2 with IC50 values of 2 nM and 52 nM for EZH2 and EZH1 respectively. It has potential antineoplastic activity.	Sci Adv, 2024, 10(13):eadk4423 JCI Insight, 2022, e155899 Cancer Discov, 2021, candisc.0913.2020
S7618	MI-2 (Menin-MLL Inhibitor)	MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.	ProQuest, 2023, 30484965 Cell Stem Cell, 2022, S1934-5909(22)00417-9 Life Sci Alliance, 2022, 5(4)e202101187
S7616	CPI-169	CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.	J Exp Clin Cancer Res, 2023, 42(1):96 J Exp Clin Cancer Res, 2023, 42(1):96 Nat Commun, 2022, 13(1):6226
S7817	MI-503	MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations.	Nat Genet, 2025, 57(1):165-179 Sci Rep, 2025, 15(1):7059 Sci Adv, 2024, 10(11):eadk0785
S8112	MS023	MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.	Biol Direct, 2025, 20(1):60 Hepatol Commun, 2025, 9(4)e0647 J Immunother Cancer, 2024, 12(9)e009603
S7983	A-196	A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50 values of 0.025 and 0.144 μM, respectively; more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.	iScience, 2023, 26(3):106158 Cancer Res, 2022, 82(8):1534-1547 Sci Total Environ, 2022, 838(Pt 1):155713
S7804	GSK503	GSK503 is a potent and specific EZH2 methyltransferase inhibitor.	JCI Insight, 2025, e177545 Int J Mol Sci, 2023, 24(10)8603 Cancer Res, 2022, CAN-22-0736
S7884	AMI-1	AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.	Cell Death Dis, 2023, 14(4):233 Oncogenesis, 2022, 11(1):45 Oncogene, 2021, 40(7):1375-1389
S7294	PFI-2 HCl	PFI-2 is a potent, selective, and cell-active lysine methyltransferase SETD7 inhibitor with K_{i (app)} and IC50 of 0.33 nM and 2 nM, 1000-fold selectivity over other methyltransferases and other non-epigenetic targets.	Biochem Biophys Res Commun, 2024, 708:149808 Life Sci Alliance, 2023, 6(5)e202201619 Pharmacol Res, 2022, 177:106122
S7832	SGC707	SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and K_d of 31 nM and 53 nM, respectively.	Cell Death Dis, 2022, 13(11):943 J Med Chem, 2020, 31 Transpl Int, 2020, 33(2):229-243
S7572	A-366	A-366 is a potent and selective G9a/GLP histone lysine methyltransferase inhibitor with IC50 of 3.3nM and 38nM, exhibiting >1000-fold selectivity for G9a/GLP over 21 other methyltransferases.	Cell Rep, 2024, 43(1):113575 Cell Mol Life Sci, 2024, 81(1):128 Cancers (Basel), 2023, 15(8)2199
S4589	Amodiaquine dihydrochloride dihydrate	Amodiaquine is a potent, non-competitive inhibitor of histamine N-methyl transferase with estimated Ki of 18.6 nM. It is also used as an antimalarial and anti-inflammatory agent.	Cell Death Differ, 2023, 10.1038/s41418-023-01167-4 Nat Biomed Eng, 2021, 10.1038/s41551-021-00718-9 J Med Chem, 2020, 31
S7619	MI-3 (Menin-MLL Inhibitor)	MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.	Cell Rep, 2025, 44(1):115219 Nat Commun, 2023, 14(1):3062 University of Calgary, 2023,
S7591	BRD4770	BRD4770 is a histone methyltransferase G9a inhibitor with IC50 of 6.3 μM, and induces cell senescence.	Adv Healthc Mater, 2024, e2401192. Hum Cell, 2023, 10.1007/s13577-023-00924-4 Cell Insight, 2023, 2(4):100112
S7575	LLY-507	LLY-507 is a cell-active, potent, and selective inhibitor of protein-lysine Methyltransferase SMYD2.	Acta Pharm Sin B, 2024, 14(2):712-728 Pharmacol Res, 2022, 177:106122 Oncol Lett, 2020, 20(5):153
S8624	Onametostat (JNJ-64619178)	Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.	Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9 Sci Rep, 2024, 14(1):4303 SLAS Discov, 2024, 29(4):100161
S7611	EI1	EI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.	NPJ Precis Oncol, 2025, 9(1):7 Cancer Res, 2018, 78(20):5731-5740 Elife, 2018, 7e35368
S4021	Tolcapone	Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with K_i of 30 nM.	FASEB J, 2022, 36(7):e22399 Viruses, 2021, 13(8)1533 Front Bioinform, 2021, 1:710591
S7820	EPZ020411 2HCl	EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM.	Theranostics, 2024, 14(10):4090-4106 Nat Commun, 2023, 14(1):1430 Inflamm Res, 2022, 71(3):309-320
S7816	MI-463	MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.	J Clin Invest, 2023, 133(13)e169993 iScience, 2023, 26(10):107726 iScience, 2023, 26(10):107726
S8209	HLCL-61 HCL	HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia.	Front Immunol, 2019, 10:174 Nat Commun, 2018, 9(1):1572 Cancer Res, 2018, 78(20):5731-5740
S8983	MAK683	MAK683 (EED inhibitor-1, example 2) is an inhibitor of embryonic ectoderm development (EED). MAK683 exhibits IC50 of 59 nM, 89 nM and 26 nM in EED Alphascreen binding, LC-MS and ELISA assay, respectively.	Nature, 2024, 10.1038/s41586-024-08031-6 Mol Cell, 2024, 84(20):3885-3898.e8 J Biol Chem, 2024, 300(10):107765
S7815	MI-136	MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes.	Breast Cancer Res, 2022, 24(1):52 Cancer Cell Int, 2022, 22(1):336 J Med Chem, 2020, 31
S3147	Entacapone	Entacapone (OR-611) inhibits catechol-O-methyltransferase(COMT) with IC50 of 151 nM. Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.	Elife, 2022, 11e72668 bioRxiv, 2021, 10.1101/2021.03.22.436393
S8147	MS049	MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively.	Theranostics, 2024, 14(10):4090-4106 Front Cell Dev Biol, 2021, 9:741736 Research Square, 2021, 10.21203/rs.3.rs-620216/v1
S7868	SAH (S-Adenosyl-L-homocysteine)	SAH (S-Adenosyl-L-homocysteine) is an inhibitor for (Methyltransferase Like 3-14) METTL3-METTL14 heterodimer complex (METTL3-14) with IC50 of 0.9 μM.	Clin Epigenetics, 2024, 16(1):18 Int J Mol Sci, 2024, 25(8)4538 Heliyon, 2023, 9(6):e16905
S8934	VTP50469	VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity.	Cell Rep Med, 2024, S2666-3791(24)00179-4 Sci Adv, 2024, 10(11):eadk0785 Cell Rep, 2023, 42(6):112547
S8494	PF-06726304	PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.	NPJ Precis Oncol, 2025, 9(1):7 Nat Commun, 2023, 10.1038/s41467-023-42930-y Elife, 2021, 10e65654
S7656	CPI-360	CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.	Mol Ther Oncolytics, 2022, 27:14-25 Cancer Res, 2018, 78(20):5731-5740
S8607	JQ-EZ-05 (JQEZ5)	JQ-EZ-05 (JQEZ5) is a specific and reversible EZH1/2 inhibitor.	Nat Chem Biol, 2019, 15(4):391-400
S8340	SGC2085	SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.	Clin Exp Med, 2025, 25(1):102 Redox Biol, 2024, 78:103414 Cell Rep, 2022, 39(12):110994
S7610^New	UNC0631	UNC 0631 is a potent inhibitor of histone methyltransferase G9a with an IC50 of 4 nM. It potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 25 nM.	Cancer Res, 2018, 78(20):5731-5740
S8070^New	UNC0224	UNC0224 is a potent and selective inhibitor G9a with an IC50 of 15 nM and a Kd of 23 nM. It can be a useful tool for investigating the biology of G9a and its roles in chromatin remodeling.
S7020	UNC0646	UNC0646 is a selective histone lysine methyltransferase (HMTase) inhibitor for G9a and GLP with IC50 of 6 nM and 15 nM , respectively, with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.
E1163	MS177	MS177 is an EZH2-targeting PRTOAC degrader and a potent inhibitor of enzymatic EZH2, that effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukemia cell growth inhibition, apoptosis, and cell cycle progression arrest.
E1728	STC-15	STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.
S6696^New	EZM 2302 (GSK3359088)	EZM2302 is an inhibitor of CARM1 enzymatic activity in biochemical assays(IC50 = 6 nM) with broad selectivity against other histone methyltransferases.
S5445	AMI-1 (free acid)	AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
S8918	MS1943	MS1943 is an orally bioavailable EZH2 selective degrader that effectively reduces EZH2 levels in cells with IC50 of 120 nM for inhibiting EZH2 methyltransferase activity.	Nat Commun, 2024, 15(1):9755
E2911	UZH2	UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM in TR-FRET assay.
S8702	EBI-2511	EBI-2511 is a highly potent and orally active EZH2 inhibitor with an IC50 of 4 nM for EZH2(A667G).
S9659	UNC6852	UNC6852 is a selective degrader that targets polycomb repressive complex 2 (PRC2) with IC50 of 247 nM for EED. UNC6852 is based on PROTAC and contains an EED226-derived ligand and a ligand for VHL.
E1967^New	ORIC-944	ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. It exhibits anti-tumor activity in vivo prostate cancer models.
S7833	OICR-9429	OICR-9429 is a potent antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3 and reduces viability of acute myeloid leukemia cells in vitro. It binds to WDR5 with high affinity (KD = 93 ± 28 nM.	FASEB J, 2025, 39(8):e70543 Mol Cell, 2024, 84(8):1475-1495.e18 PLoS Biol, 2024, 22(3):e3002240
S2184	WDR5-0103	WDR5-0103 (WD-Repeat Protein 5-0103) is a small-molecule antagonist of WDR5 (WD40 repeat protein 5) with Kd of 450 nM.	J Clin Invest, 2023, 133(13)e169993 Cancer Res, 2023, 83(16):2750-2762 Cell Rep, 2023, 42(9):113145
S8359	UNC3866	UNC3866 is a potent antagonist of the methyllysine (Kme) reading function of the Polycomb CBX and CDY families of chromodomains. UNC3866 binds the chromodomains of CBX4 and CBX7 most potently, with a K(d) of ∼100 nM for each, and is 6- to 18-fold selective as compared to seven other CBX and CDY chromodomains.	Leukemia, 2021, 10.1038/s41375-021-01121-8 Leukemia, 2021, 10.1038/s41375-021-01121-8 Int J Mol Sci, 2021, 22(2)E619
S7610^New	UNC0631	UNC 0631 is a potent inhibitor of histone methyltransferase G9a with an IC50 of 4 nM. It potently reduces H3K9me2 levels in MDA-MB-231 cells with an IC50 of 25 nM.	Cancer Res, 2018, 78(20):5731-5740
F0057^New	Histone H3 Rabbit mAb		Nanotoxicology, 2021, 15(6):779-797
F0165^New	Histone H3 (tri methyl Lys 27) Rabbit mAb	Histone H3 (tri methyl K27),trimethyl-Histone H3 (Lys27),Tri-Methyl-Histone H3 (Lys27),Trimethyl-Histone H3 (Lys27) - ChIP Validated
F0784^New	Histone H2B Rabbit mAb	Histone H2B
F2863^New	Tri-Methyl-Histone H3 (Lys4) (J19C19) Rabbit mAb	ChIPAb+ Trimethyl-Histone H3 (Lys4) - ChIP Validated,Histone H3 (tri methyl K4),Trimethyl Histone H3 (Lys4),Trimethyl-Histone H3 (Lys4),Tri-Methyl-Histone H3 (Lys4)
F0669^New	Acetyl-Histone H3 (Lys18) Rabbit mAb	Acetyl-Histone H3 (Lys18),Histone H3 (acetyl K18)
F0329^New	Di-Methyl-Histone H3 (Lys27) Rabbit mAb	dimethyl-Histone H3 (Lys27),Di-Methyl-Histone H3 (Lys27),Histone H3 (di methyl K27)	Front Cell Dev Biol, 2025, 13:1566567
F1267^New	Tri-Methyl-Histone H4 (Lys20) Rabbit mAb	Histone H4 (tri methyl K20),trimethyl-Histone H4 (Lys20),Tri-Methyl-Histone H4 (Lys20)
F0639^New	Mono-Methyl-Histone H3 (Lys 4) Rabbit mAb	Histone H3 (mono methyl K4),monomethyl-Histone H3 (Lys4),Mono-Methyl-Histone H3 (Lys4)
F2529^New	Histone H3 (tri methyl Lys 27) mAb	Histone H3 (tri methyl K27),trimethyl-Histone H3 (Lys27),Tri-Methyl-Histone H3 (Lys27),Trimethyl-Histone H3 (Lys27) - ChIP Validated
F3394^New	Histone H3 (tri methyl Lys 9) Rabbit mAb	Histone H3 (tri methyl K9),Histone H3 [Trimethyl Lys9],trimethyl-Histone H3 (Lys9),Tri-Methyl-Histone H3 (Lys9)
F0307^New	SUZ12 Rabbit mAb
F3402^New	Histone H3 (mono methyl Lys 4) Rabbit mAb	Histone H3 (mono methyl K4),monomethyl-Histone H3 (Lys4),Mono-Methyl-Histone H3 (Lys4)
F0365^New	Tri-Methyl-Histone H3 (Lys4) Rabbit mAb	ChIPAb+ Trimethyl-Histone H3 (Lys4) - ChIP Validated,Histone H3 (tri methyl K4),Trimethyl Histone H3 (Lys4),Trimethyl-Histone H3 (Lys4),Tri-Methyl-Histone H3 (Lys4)
S8070^New	UNC0224	UNC0224 is a potent and selective inhibitor G9a with an IC50 of 15 nM and a Kd of 23 nM. It can be a useful tool for investigating the biology of G9a and its roles in chromatin remodeling.
S6696^New	EZM 2302 (GSK3359088)	EZM2302 is an inhibitor of CARM1 enzymatic activity in biochemical assays(IC50 = 6 nM) with broad selectivity against other histone methyltransferases.
E1967^New	ORIC-944	ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. It exhibits anti-tumor activity in vivo prostate cancer models.

Choose Selective Histone Methyltransferase Inhibitors